Skip to main content

Blood Bank

Cost Analysis & Reimbursement

In the modern healthcare environment, the laboratory is often viewed as a “cost center” - a department that consumes resources - rather than a “revenue center.” Consequently, Blood Bank administration requires a sophisticated understanding of how costs are accrued (Cost Analysis) and how the hospital is paid for services rendered (Reimbursement). This financial relationship dictates decision-making regarding staffing, test menu formulation, and technology acquisition. An entry-level laboratory scientist must understand that clinical decisions have direct financial consequences

Cost Analysis (Micro-costing)

Cost analysis is the internal process of determining exactly how much it costs the laboratory to generate a single reportable result. This figure, often called the Cost Per Test, is the baseline for setting prices (the Chargemaster) and negotiating contracts

Components of the Cost Per Test

To calculate the true cost of a test (e.g., an Antibody Screen), the manager must aggregate several distinct financial elements:

  • Direct Material Costs: The cost of consumables used specifically for that test
    • Examples: Reagents (anti-IgG), control cells, the gel card or microplate, pipettes, and tubes. In Blood Bank, this also includes the cost of the blood product itself (the unit of RBCs purchased from the supplier) if calculating the cost of a transfusion
  • Direct Labor Costs: The cost of the personnel time required to perform the test
    • Calculation: (Average hourly wage + Benefits) × (Minutes per test / 60)
    • Impact: Manual tube testing has high labor costs; automation has low labor costs
  • Indirect Costs (Overhead): Expenses that cannot be traced to a single test but are necessary for operation
    • Allocation: These are usually applied as a surcharge or percentage
    • Examples: Electricity, LIS maintenance fees, instrument depreciation, proficiency testing, accreditation fees, and the salary of the laboratory manager

Break-Even Analysis

This analysis helps the laboratory decide whether to perform a test in-house or send it to a reference laboratory. It identifies the volume of testing required to cover the costs of operation

  • The Break-Even Point: The volume where Total Revenue equals Total Costs
    • Equation: \(\text{Break-Even Volume} = \text{Fixed Costs} / (\text{Revenue per Test} - \text{Variable Cost per Test})\)
  • Application: If the lab wants to buy a molecular genotyping analyzer, they must calculate how many genotypes they need to run per year to pay for the machine. If the demand is below the break-even point, it is financially sounder to send the tests to a reference lab, even if the reference lab fee is high

Reimbursement Models

Reimbursement describes how the hospital or laboratory gets paid by third-party payers (Medicare, Medicaid, Private Insurance). The payment model differs significantly depending on whether the patient is an Inpatient or an Outpatient

Inpatient Reimbursement: Prospective Payment System (PPS)

For patients admitted to the hospital, reimbursement is generally based on the Diagnosis Related Group (DRG)

  • The Mechanism: The hospital receives a fixed, lump-sum payment based on the patient’s diagnosis (e.g., “Surgical Procedure for Hip Replacement”)
  • Laboratory Impact: In this model, the laboratory is a Cost Center
    • The payment for the hip surgery includes an allowance for “lab work.”
    • If Blood Bank performs 2 Type and Screens or 10 Type and Screens, the hospital gets paid the exact same amount
    • Financial Strategy: The goal is utilization management - reducing unnecessary testing to preserve the profit margin within the fixed DRG payment

Outpatient Reimbursement: Fee-For-Service

For patients seen in the ER, clinics, or ambulatory surgery, reimbursement is often based on the Fee Schedule

  • The Mechanism: Each test performed is billed individually
  • Ambulatory Payment Classifications (APCs): Similar to DRGs but for outpatients; tests are often “bundled.” For example, if a patient has a transfusion, the Type and Screen might be bundled into the payment for the transfusion procedure rather than paid separately
  • Laboratory Impact: In this model, the laboratory generates distinct revenue. However, payment is capped by the Clinical Laboratory Fee Schedule (CLFS), which is often lower than the lab’s “List Price” (Chargemaster)

Coding & Billing Compliance

To be reimbursed, the laboratory must translate “medical acts” into standardized “codes” that insurance computers can process. Errors in coding lead to Claim Denials, which are lost revenue

CPT Codes (Current Procedural Terminology)

Maintained by the AMA, these codes describe what was done

  • 86900: ABO Blood Typing
  • 86901: Rh Blood Typing
  • 86850: Antibody Screen
  • 86870: Antibody Identification
  • 86920: Compatibility Test (Crossmatch), immediate spin
  • Paneling/Unbundling: A major compliance issue. If a specific code exists for a “panel” of tests, the lab cannot bill for the components individually to get more money. This is considered fraud

HCPCS Level II Codes (“P-Codes”)

While CPT codes bill for the procedure (the act of typing or crossmatching), Blood Bank is unique because it also bills for the product. HCPCS codes describe the biological product

  • P9016: Red Blood Cells, Leukoreduced
  • P9019: Platelets
  • Significance: The lab bills for the crossmatch (CPT) and the unit of blood (HCPCS)

ICD-10 Codes (International Classification of Diseases)

These codes describe why the test was done (Medical Necessity)

  • The Link: For a claim to be paid, the ICD-10 code (Diagnosis) must justify the CPT code (Test)
  • Example: A claim for “ABO/Rh Typing” (CPT 86900) will be paid if linked to “Pregnancy” or “Pre-op exam.” It may be denied if linked to “Dermatitis.”

Revenue Cycle Management Issues

Financial success depends on the “Revenue Cycle” - the path from the doctor’s order to the cash in the bank

  • Advance Beneficiary Notice (ABN): If the lab suspects Medicare will not pay for a test (because it is experimental or not medically necessary for that diagnosis), the patient must sign an ABN before the test is drawn. This accepts financial responsibility. If the test is run without an ABN and Medicare denies the claim, the lab cannot bill the patient; the cost must be written off
  • Correct Coding Initiative (CCI) Edits: Automated rules in the billing software that prevent incompatible codes from being billed together. For example, you typically cannot bill for an “Electronic Crossmatch” and a “Serologic Crossmatch” on the same unit
  • The Chargemaster (CDM): The master list of all billable items and their prices. This must be updated annually. The “Price” listed in the CDM is rarely what the hospital gets paid; it is usually significantly higher than the negotiated reimbursement rate